Generic Name: natalizumab
Brand Name: Tysabri
Manufacturer: Biogen Canada, Inc.
Therapeutic Area: Multiple Sclerosis, relapsing-remitting
Indications: Tysabri (intravenous, IV; and subcutaneous, SC) is indicated as monotherapy for the treatment of patients with the relapsing-remitting form of multiple sclerosis (MS) to reduce the frequency of clinical exacerbations, to decrease the number and volume of active brain lesions identified on magnetic resonance imaging (MRI) scans and to delay the progression of physical disability. Tysabri is generally recommended in MS patients who have had an inadequate response to, or are unable to tolerate, other therapies for multiple sclerosis.
Manufacturer Requested Reimbursement Criteria1: Tysabri SC to be funded in similar manner as Tysabri IV.
Submission Type: Initial
Project Status: Pending
Call for patient/clinician input open: April 5, 2021
Call for patient/clinician input closed: May 14, 2021
Anticipated Date: April 21, 2021
Fee Schedule: Pending
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.